Lupin Healthcare has announced the launch of the Luforbec beclometasone/formoterol MDI in the UK. The generic version of Chiesi’s Fostair MDI was approved by the MHRA for the treatment of asthma and COPD in June 2021. According to Lupin, the Luforbec inhaler will be manufactured at the company’s facilities in the US and India.
The company cited UK prescribing data showing that the UK National Health Service spent more than £177 million to purchase Fostair MDIs in the year ending May 2021.
Read the Lupin press release.
